Pillar Biosciences Launches oncoReveal Core LBx, an NGS Kit to Enable Localized Liquid Biopsy-Based Tumor Profiling

Research Use Only (RUO) NGS Kit will provide a simple, automatable, industry-leading liquid biopsy workflow

NATICK, Mass. – September 19, 2023 – (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the global launch of oncoReveal Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit that will provide the foundation for laboratories to develop their own liquid biopsy-based pan-cancer tumor profiling tests. The oncoReveal Core LBx is the latest addition to Pillar Biosciences’ portfolio of RUO and IVD cancer profiling products.

The oncoReveal Core LBx panel interrogates 104 clinically relevant genes in one multiplex reaction and has a fully automatable workflow that can be performed by any laboratory. With a turn-around time (TAT) under three days and the capacity to batch more than 20 liquid biopsy samples on a single Illumina NextSeq™ run, the oncoReveal Core LBx panel provides both the economic value and scale of sequencing necessary to accurately profile circulating cell-free tumor DNA (cfDNA) at extremely high levels of sensitivity and specificity.

“We are excited to launch oncoReveal Core LBx, specifically designed to meet the emerging needs of laboratories looking for scalable and efficient NGS-based liquid biopsy profiling workflow,” said Randy Pritchard, CEO of Pillar Biosciences. “Currently, the market is dependent on large national commercial reference labs to perform liquid biopsy testing, which is both expensive and time consuming”.

The oncoReveal Core LBx analyzes cfDNA present in plasma for genetic alterations in cancer samples, including assessment of MSI. With mutation detection performance as low as 0.1%, oncoReveal Core LBx provides highly accurate tumor profiling data. oncoReveal Core LBx is powered by PiVAT®, an automated secondary bioinformatics software that supports the identification of somatic mutations from cell-free DNA with high sensitivity and specificity. Pillar Biosciences’ proprietary PiVAT technology is fully compatible with third-party clinical data reporting solutions.

About Pillar Biosciences

Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes the selection of precision therapies for cancer patients, from tumor profiling to therapy selection and recurrence monitoring. Pillar’s NGS testing solutions, including oncoReveal CDx pan-cancer solid tumor IVD, currently under review by FDA, are powered by its proprietary SLIMamp® and PiVAT® technologies, and decentralize the testing process, reducing diagnostic costs and improving access and efficiency of complex NGS testing for clinicians healthcare providers,, patients and researchers globally. In addition to its IVD products, the company has more than 20 NGS testing kits available in RUO formats, and several others in various stages of development, including a tumor-informed MRD assay. Pillar Biosciences has operations in Natick, MA. For more information visit pillarbiosci.com and connect with us on LinkedIn.

More Information:

Brian Wright
602-540-9522
wrightb@pillarbiosci.com